[ad_1]
Company announcement
Copenhagen, Denmark; February 26, 2021 – Genmab A / S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of transactions carried out in Genmab A / S (Nasdaq: GMAB) carried out by management employees and their closely associated persons.
The senior executives of the company and their closely associated persons have mandated Genmab A / S on their behalf to publish transactions in Genmab shares carried out by the senior executives of the company and their closely associated persons.
About Genmab
Genmab is an international biotechnology company whose primary goal is to improve the lives of cancer patients. Founded in 1999, Genmab is the creator of several approved therapeutic antibodies which are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next generation antibody technologies, expertise in antibody biology, translational research and data science, and strategic partnerships. To create new therapies, Genmab uses its next generation antibody technologies, which are the result of its collaborative corporate culture and a deep passion for innovation. Genmab’s proprietary pipeline consists of engineered antibody candidates, including bispecific T-cell engaging agents and next-generation immune checkpoint modulators, enhanced effector antibodies, and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark, with sites in Utrecht, the Netherlands, Princeton, New Jersey, the United States and Tokyo, Japan. For more information, please visit Genmab.com.
Contact:
Marisol Peron, Senior Vice President, Global Investor Relations and Communications
T: +1 609 524 0065; E: [email protected]
For investor relations:
Andrew Carlsen, Senior Director, Head of Investor Relations
T: +45 3377 9558; E: [email protected]
This company announcement contains forward-looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward-looking statements. Actual results or performance may differ materially from future results or performance expressed or implied in such statements. Important factors that could cause our actual results or performance to vary materially include, but are not limited to, risks associated with preclinical and clinical product development, uncertainties associated with the results and conduct of clinical trials, including unforeseen safety issues, product manufacturing uncertainties, lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our industry and markets, our inability to attract and retain suitably qualified personnel, the inapplicability or lack of protection of our patents and rights, our relationships with affiliated entities, technological changes and developments which may render our products or technologies obsolete, and other factors. For a more in-depth analysis of these risks, please refer to the risk management sections of Genmab’s latest financial reports, available at www.genmab.com and the risk factors included in Genmab’s most recent annual report on Form 20-F and other filings from the United States Securities and Exchange Commission (SEC), available at www.sec.gov. Genmab assumes no obligation to update or revise any forward-looking statements in this Company Announcement or to confirm such statements to reflect subsequent events or circumstances after the date of publication or in connection with actual results, unless the law requires it.
Genmab A / S and / or its subsidiaries own the following brands: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® and Kesimpta® are trademarks of Novartis AG or its subsidiaries. DARZALEX® and DARZALEX FASPRO® are registered trademarks of Janssen Pharmaceutica NV. TEPEZZA® is a trademark of Horizon Therapeutics plc.
CVR no. 2102 3884
LEI code 529900MTJPDPE4MHJ122
Genmab A / S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
-
210226_CA14_Managerial Employees_transactions
Source link
